- Market Capitalization, $K 29,419
- Shares Outstanding, K 13,747
- Annual Sales, $ 0 K
- Annual Income, $ -3,260 K
- 60-Month Beta -1.38
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 9.86
|Period||Period Low||Period High||Performance|
| || |
-0.30 (-13.10%)since 08/20/21
| || |
-0.91 (-31.38%)since 06/21/21
| || |
-5.15 (-72.13%)since 09/21/20
A series of recent pre-clinical reports demonstrates LB-100's effectiveness in various
A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently Initiated...
LixteBiotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating...
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) ("Lixte" or the "Company") noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine's Cancer Biology...
Presentation to highlight Company's current clinical study of lead compound LB-100 for Small Cell Lung Cancer
-- Due to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit in patients may be seen in this early-stage clinical trial
Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair.
Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments
-- Lixte's pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100